nach oben

Journal of Thrombosis and Thrombolysis

Erschienen in:

06.02.2018

A rare CALR variant mutation and a review of CALR in essential thrombocythemia

verfasst von: Robert Diep, Ara Metjian

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Essential thrombocythemia (ET) is an indolent myeloproliferative neoplasm characterized by megakaryocyte hyperplasia, thrombocytosis, thrombotic and hemorrhagic complications, and potential transformation into myelofibrosis and acute myeloid leukemia. The vast majority of cases are driven by a somatic mutation in JAK2, CALR, or MPL. CALR, a gene that codes for the calcium-binding chaperone calreticulin, is the predominant mutation in patients with non-mutated JAK2 essential thrombocythemia, accounting for 20–25% of the overall somatic mutation frequency in ET. In this brief review of ET, we introduce a rare CALR mutation through a case presentation of a 58-year-old man with diffuse pulmonary emboli in the setting of thrombocytosis. We subsequently characterize the main types of CALR mutations and their value in diagnosis and prognosis of disease course, and lastly discuss the current clinical approach to ET.

Deadmond MA, Smith-Gagen JA (2015) Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973–2011. J Cancer Res Clin Oncol 141(12):2131–2138. https://doi.org/10.1007/s00432-015-1983-5 CrossRefPubMed

Tefferi A, Barbui T (2015) Essential thrombocythemia and polycythemia vera: focus on clinical practice. Mayo Clin Proc 90(9):1283–1293. https://doi.org/10.1016/j.mayocp.2015.05.014 CrossRefPubMed

Elliott MA, Tefferi A (2005) Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128(3):275–290. https://doi.org/10.1111/j.1365-2141.2004.05277.x CrossRefPubMed

Gangat N, Wolanskyj AP, Tefferi A (2006) Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications. Eur J Haematol 77(4):327–333. https://doi.org/10.1111/j.1600-0609.2006.00715.x CrossRefPubMed

Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant’Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schonegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379–2390. https://doi.org/10.1056/NEJMoa1311347 CrossRefPubMed

Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O’Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJ, Harrison CN, Cross NC, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391–2405. https://doi.org/10.1056/NEJMoa1312542 CrossRefPubMedPubMedCentral

Chen CC, Gau JP, Chou HJ, You JY, Huang CE, Chen YY, Lung J, Chou YS, Leu YW, Lu CH, Lee KD, Tsai YH (2014) Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia. Ann Hematol 93(12):2029–2036. https://doi.org/10.1007/s00277-014-2151-8 CrossRefPubMed

Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, Fanelli T, Bosi A, Vannucchi AM, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative I (2014) Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 123 (10):1552–1555. https://doi.org/10.1182/blood-2013-11-538983 CrossRefPubMed

CALR calreticulin [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004 – [cited 2017/05/20]. https://www.ncbi.nlm.nih.gov/gene/811

10.

Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, Cavalloni C, Sant’Antonio E, Abbonante V, Moccia F, Casetti IC, Bellini M, Renna MC, Roncoroni E, Fugazza E, Astori C, Boveri E, Rosti V, Barosi G, Balduini A, Cazzola M (2016) Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 30(2):431–438. https://doi.org/10.1038/leu.2015.277 CrossRefPubMed

11.

Luo W, Yu Z (2015) Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs). Stem Cell Investig 2:16. https://doi.org/10.3978/j.issn.2306-9759.2015.08.01 PubMedPubMedCentral

12.

Ha JS, Kim YK (2015) Calreticulin exon 9 mutations in myeloproliferative neoplasms. Ann Lab Med 35(1):22–27. https://doi.org/10.3343/alm.2015.35.1.22 CrossRefPubMed

13.

Kollmann K, Warsch W, Gonzalez-Arias C, Nice FL, Avezov E, Milburn J, Li J, Dimitropoulou D, Biddie S, Wang M, Poynton E, Colzani M, Tijssen MR, Anand S, McDermott U, Huntly B, Green T (2017) A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation. Leukemia 31(4):934–944. https://doi.org/10.1038/leu.2016.280 CrossRefPubMed

14.

Lau WW, Hannah R, Green AR, Gottgens B (2015) The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patients. Blood 125(10):1679–1681. https://doi.org/10.1182/blood-2014-12-618074 CrossRefPubMedPubMedCentral

15.

Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Pacilli A, Vannucchi AM, Passamonti F (2014) Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 89(8):E121–E124. https://doi.org/10.1002/ajh.23743 CrossRefPubMed

16.

Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant’Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (2014) Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 124(7):1062–1069. https://doi.org/10.1182/blood-2014-05-578435 CrossRefPubMedPubMedCentral

17.

Barbui T, Thiele J, Vannucchi AM, Tefferi A (2015) Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J 5:e337. https://doi.org/10.1038/bcj.2015.64 CrossRefPubMedPubMedCentral

18.

Tefferi A, Pardanani A (2014) Genetics: CALR mutations and a new diagnostic algorithm for MPN. Nat Rev Clin Oncol 11(3):125–126. https://doi.org/10.1038/nrclinonc.2014.16 CrossRefPubMed

19.

Finazzi G, Carobbio A, Guglielmelli P, Cavalloni C, Salmoiraghi S, Vannucchi AM, Cazzola M, Passamonti F, Rambaldi A, Barbui T (2014) Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood 124(16):2611–2612. https://doi.org/10.1182/blood-2014-08-596676 CrossRefPubMed

20.

Tefferi A, Barbui T (2015) Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 90(2):162–173. https://doi.org/10.1002/ajh.23895 CrossRefPubMed

21.

Angona A, Fernandez-Rodriguez C, Alvarez-Larran A, Camacho L, Longaron R, Torres E, Pairet S, Besses C, Bellosillo B (2016) Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing. Blood Cancer J 6(8):e463. https://doi.org/10.1038/bcj.2016.75 CrossRefPubMedPubMedCentral

22.

Yao QM, Zhou J, Gale RP, Li JL, Li LD, Li N, Chen SS, Ruan GR (2015) A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms. Hematology 20(9):517–522. https://doi.org/10.1179/1607845415Y.0000000009 CrossRefPubMed

23.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d’Amore ES, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, Mullauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 29(23):3179–3184. https://doi.org/10.1200/JCO.2010.34.5298 CrossRefPubMed

24.

Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A (2012) Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120(26):5128–5133. https://doi.org/10.1182/blood-2012-07-444067 (quiz 5252)CrossRefPubMed

25.

Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Finazzi G, Carobbio A, Thiele J, Passamonti F, Falcone C, Tefferi A (2015) Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J 5:e369. https://doi.org/10.1038/bcj.2015.94 CrossRefPubMedPubMedCentral

26.

Rumi E, Cazzola M (2016) How I treat essential thrombocythemia. Blood 128(20):2403–2414. https://doi.org/10.1182/blood-2016-05-643346 CrossRefPubMed

27.

Patrono C, Rocca B, De Stefano V (2013) Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood 121(10):1701–1711. https://doi.org/10.1182/blood-2012-10-429134 CrossRefPubMed

28.

Duvall D (2011) Therapeutic cytapheresis: too many platelets, too many white blood cells. J Clin Apher 26(1):47–52. https://doi.org/10.1002/jca.20266 CrossRefPubMed

29.

Pieri L, Pancrazzi A, Pacilli A, Rabuzzi C, Rotunno G, Fanelli T, Guglielmelli P, Fjerza R, Paoli C, Verstovsek S, Vannucchi AM (2015) JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. Blood 125(21):3352–3353. https://doi.org/10.1182/blood-2015-01-624536 CrossRefPubMed

30.

Lin Y, Liu E, Sun Q, Ma J, Li Q, Cao Z, Wang J, Jia Y, Zhang H, Song Z, Ai X, Shi L, Feng X, Li C, Wang J, Ru K (2015) The prevalence of JAK2, MPL, and CALR mutations in chinese patients with BCR-ABL1-negative myeloproliferative neoplasms. Am J Clin Pathol 144(1):165–171. https://doi.org/10.1309/AJCPALP51XDIXDDV CrossRefPubMed

Titel: A rare CALR variant mutation and a review of CALR in essential thrombocythemia
verfasst von: Robert Diep
Ara Metjian
Publikationsdatum: 06.02.2018
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 3/2018
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-018-1619-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

A rare CALR variant mutation and a review of CALR in essential thrombocythemia

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Update Innere Medizin

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Comparative outcomes of thrombocytopenic acute leukemic patients with venous thromboembolism at a Comprehensive Cancer Center

Mind the gap: results of a multispecialty survey on coordination of care for peri-procedural anticoagulation

Highlights from the 2017 American Heart Association Scientific Sessions in Anaheim, California

Do telehealth interventions improve oral anticoagulation management? A systematic review and meta-analysis

Risk of discontinuation of clopidogrel after 1 month following bare-metal stents: a propensity-score adjusted comparison with continued administration of clopidogrel after drug-eluting stents

Does my patient have a pulmonary embolism? The Wells vs. PISA 2 rule in orthopedic patients

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Update Innere Medizin